Comparison of Ciprofloxacin-Based Triple Therapy with Conventional Triple Regimen for Helicobacter pylori Eradication in Children
-
Fatemeh Farahmand
,
Tayebeh Mohammadi
,
Mehri Najafi
,
Gholamhosein Fallahi
,
Ahmad Khodadad
,
Farzaneh Motamed
,
Sayed Mahdi Marashi
,
Maryam Shoaran
,
Raheleh Nabavizadeh Rafsanjani
Abstract
Helicobacter pylori infection is a prevalent disease among Iranian children. The purpose of this study was to compare the effect of ciprofloxacin and furazolidone on eradicating helicobacter pylori in Iranian children in combination with amoxicillin and omeprazole. In this cohort study, helicobacter pylori infection was confirmed by gastroscopy, rapid urease test or pathologic assessments. A total of 66 children were randomly enrolled; based on the random number table, and were divided into two groups; first, a combination regimen consisting of ciprofloxacin, amoxicillin, and omeprazole; second, a three-medication regimen consisting of amoxicillin, furazolidone, and omeprazole. The effect of both medical regimens on the successful eradication of helicobacter pylori infection was assessed and compared. Chi-square test was used for evaluating the association between quantitative variables. All comparisons were made at the significance of P<0.05. Endoscopic tests prior to initiating treatments showed that 66.7% of the patients had a degree of nodularity while peptic ulcer was only observed in one patient. One month after the end of the treatments, eradication of the helicobacter pylori infection was reported 87.9% (29/33) in the first group (CAO) and 60.6% (20.33) in the second group (FAO) (P=0.011). It appears that a major advantage of our proposed regimen over others is a lack of wide use of fluoroquinolones for treating children’s diseases. Given FDA’s recommendation about the possibility of prescribing ciprofloxacin for infected patients with multidrug resistance, we can use the regimen proposed in this study in patients with resistance to standard treatments.
Gold BD, Colletti RB, Abbott M, Czinn SJ, Elitsur Y, Hassall E, et al. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7.
Bourke B, Ceponis P, Chiba N, Czinn S, Ferraro R, Fischbach L, et al. Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents-- an evidence-based evaluation. Can J Gastroenterol 2005;19:399-408.
Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720-41.
Wotherspoon AC, Ortiz-Hidalgo C, Falzon M, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-6.
Houben D, De Beek V, Hensen AJM, de Craen AJ, RauwsEA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy--the important of antimicrobial resistance on eradication rate. Alimentary Pharmacol Ther 1999;13:1047-55.
Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastricm lymphoma. N Engl J Med 1994;330:1267-9.
Nazifi A. Effect of omeprazole plus ciprofloxacin on the healing of duodenal ulcer and eradication of helicobacter pylori. Razi J Med Sci 2001;8:175-9.
Khodad A, Khtami GhR, Hatmi ZN, Karami H. Effectiveness of combination therapy with honey in H.Pylori eradication in Pediatrics Medical Centre. Tehran Univ Med J 2006;64:78-87.
Saneeyan H, Layegh S, Rahimi H. Effectivness of Probiotic on Treatment of Helicobacter pylori Infection in Children. J Isfahan Med School 2011;29:882-9.
Torres J. Epidemiologic and clinical aspects of Helicobacter pylori infection in children. Rev Gastroenterol Mex 2000;65:13-9.
Najafi M, Sobhani M, Khodadad A, Farahmand F, Motamed F. Reinfection Rate after Successful Helicobacter pylori Eradication in children. Iran J Pediatr 2010;20:58-62.
Joette M, Meyer, Pharm D, Siepman NY, Sugg JE, Morris D, et al. Risk Factors for Helicobacter pylori Resistance in the United States :The Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP)Study, 1993-1999. Ann Intern Med 2002;136:13-24.
Falsafi T, Mobasheri F, Nariman F, Najafio M. Susceptibilities to different antibiotics of helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol 2004;42:387-9.
Kohantab J, Bazargani A, Saber Firoozi M, Mobasser A. Antimicrobial susceptibility testing of helicobcter pylori to selected agents by agar dilution method in Shiraz-Iran. Indian J Med Microbiol 2007;25:374-7.
Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 2008;60:409-15.
Toshihiro N, Hidekazu S, Toshifumi H. Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication .JClin Biochem Nutr 2009;44:119-24.
Najafi M, Khodadad A, Fallahi G, farahmand F, Motamed F, Sobhani M. Success Rate of Furazolidone-Based Triple Therapy for Eradication of Helicobacter pylori in Children. Iran J Pediatr 2008;19:244-8.
Bannon MJ, Stutchfield PR, Weindling AM, Damjanovic V. Ciprofloxacin in neonatal Enterobacter cloacae septicaemia. Arch Dis Childhood 1989;64:1388-91.
Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL,Pendergrass T. Ciprofloxacin and Amoxicillin as Continuation Treatment of Febrile Neutropenia in Pediatric Cancer Patients. Med Pediatr Oncol 2003;40:93-8.
Hashemi S, Hajiani E, Masjedizadeh A, Shayesteh A, Abooali A. Comparison of a triple therapy regimen containing ciprofloxacin and low dose furazolidone with conventional quadruple regimen for Helicobacter pylori eradication. Sci Med J 2010;8:445-54.
Finizio R, Nista EC, Candelli M, Zocco MA. Levofloxacin-based triple therapy in second-line treatment for helicobacter pylori eradication. Helicobacter 2005;10:485-556.
Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs quadruple therapy as second-line treatment of resistant helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:421-7.
Yousef AA, Fryer CJH, Chedid FD, Abbas AA, Felimban SK, Khattab TM. A Pilot Study of Prophylactic Ciprofloxacin During Delayed Intensification in Children With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 2004;43:637-43.
Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofl oxacin safety in paediatrics: a systematic review. Arch Dis Child 2011;96:874-80.
Sykora J, Siala K, Varvarovska J, Pazdiora P, PomahacováR, Huml M. Epidemiology of Helicobacter pylori Infection in Asymptomatic Children: A Prospective Population-Based Study from the Czech Republic. Application of a Monoclonal-Based Antigen-in-Stool Enzyme Immunoassay. Helicobacter 2009;14:286-97.
Mahalanabis D, Rahman MM, Sarker SA, Bardhan PK, Hildebrand P, Beglinger C, et al. Helicobacter pylori Infection in the Young in Bangladesh: Prevalence, Socioeconomic and Nutritional Aspects. Int J Epidemiol 1996;25:894-8.
Francavilla R, Lionetti E, Castellaneta SP, MagistàAM, Boscarelli G, Piscitelli D, et al. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005;129:1414-9.
Lionetti E, Miniello VL, Castellaneta SP, Magistá AM, de Canio A, Maurogiovanni G, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 2006;24:1461-8.
Haghi-Ashtiani MT, Monajemzadeh M, Motamed F, Mahjoub F, Sharifan M, Shahsiah R, et al. Anemia in Children with and without Helicobacter pylori Infection. Arch Med Res 2008;39:536-40.
Luzza F, Pensabene L, Imeneo M, Mancuso M, Contaldo A, Giancotti L, et al. Antral nodularity identifies childreninfected with Helicobacter pylori with higher grades ofgastric inflammation. Gastrointest Endosc 2001;53:60-4.
Prasad KK, Thapa BR, Sharma AK, Nain CK, Singh K. Reassessment of diagnostic value of antral nodularity forHelicobacter pylori infection in children. MinervaGastroenterol Dietol 2008;54:1-6.
Tindberg Y, Nyrén O, Blennow M, Granstrom M.Helicobacter pylori infection and abdominal symptomsamong Swedish school children. J Pediatr Gastroenterol Nutr 2005;41:33-8.
Cherian S, Burgner DP, Cook AG, Sanfilippo FM, Forbes DA. Associations between Helicobacter pylori infection, co-morbid infections, gastrointestinal symptoms, andcirculating cytokines in African children. Helicobacter 2010;15:88-97
Motamed F, Doroudian R, Najafi M, Monajemzade M, Marashi SM, Arastoo L, et al. Helicobacter pylori infection: Clinical, Endoscopic and Pathological findings in Iranian children. Int J Pediatr 2014;2: 9-17.
Kazemi S, Tavakkoli H, Habizadeh MR, Emami MH. Diagnostic values of Helicobacter pylori diagnostic tests:stool antigen test, urea breath test, rapid urease test,serology and histology. J Res Med Sci 2011;16:1097-104.
Amini M, Khedmat H, Yari F. Eradication rate of helicobacter pylori in dyspeptic patients. Med Sci Monit 2005;11:CR193-5.
Dresner D, Coyle W. Efficacy of ciprofloxacin in the eradication of helicobacter pylori. South Med J 1996;89:775-8.
Rafeey M, Ghotaslou R, Nikvash S, Hafez AA. Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother 2007;13:291-5
Kohantab J, Bazargani A, Saber Firoozi M, Mobaser A.Antimicrobial susceptibility testing of helicobcter pylori to selected agents by agar dilution method in Shiaz-Iran.Indian J Med Microbiol 2007;25:374-7.
Fock KM, Chelvam P, Lim SG. Triple therapy in theeradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. Aliment Pharmacol Ther 2000;14: 225-31.
Khademi F, Faghri J, Poursina F, Esfahani BN, Moghim S, Fazeli H, et al. Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran. J Res Med Sci 2013;18:1056-60.
| Files | ||
| Issue | Vol 54, No 6 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Helicobacter pylori Children Eradication Ciprofloxacin Furazolidone | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
